Organogenesis Holdings Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ORGO$0.91+11.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(amounts in thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $109,965 | $135,571 |
| Restricted cash | 569 | 580 |
| Accounts receivable, net | 103,320 | 109,861 |
| Inventories, net | 29,338 | 26,219 |
| Asset held for sale (Note 6) | 7,033 | — |
| Prepaid expenses and other current assets | 17,935 | 13,710 |
| Total current assets | 268,160 | 285,941 |
| Property and equipment, net | 75,518 | 89,128 |
| Intangible assets, net | 11,626 | 12,468 |
| Goodwill | 28,772 | 28,772 |
| Operating lease right-of-use assets, net | 36,756 | 37,110 |
| Deferred tax asset, net | 40,728 | 39,462 |
| Other assets | 5,834 | 5,005 |
| Total assets | $467,394 | $497,886 |
| Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity | ||
| Current liabilities: | ||
| Current portion of finance lease obligations | $1,193 | $1,170 |
| Current portion of operating lease obligations - related party | 3,712 | 3,671 |
| Current portion of operating lease obligations | 4,353 | 4,272 |
| Accounts payable | 24,660 | 28,911 |
| Accrued expenses and other current liabilities | 31,135 | 39,453 |
| Total current liabilities | 65,053 | 77,477 |
| Finance lease obligations, net of current portion | 411 | 718 |
| Operating lease obligations, net of current portion - related party | 7,339 | 8,283 |
| Operating lease obligations, net of current portion | 25,625 | 25,198 |
| Other liabilities | 897 | 894 |
| Total liabilities | 99,325 | 112,570 |
| Commitments and contingencies (Note 15) | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding at March 31, 2025 and December 31, 2024; liquidation preference of $134,014 and $131,387 at March 31, 2025 and December 31, 2024, respectively. | 125,167 | 122,419 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 870,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; none issued or outstanding | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized; 127,582,084 and 126,458,784 shares issued; 126,853,536 and 125,730,236 shares outstanding at March 31, 2025 and December 31, 2024, respectively. | 13 | 13 |
| Additional paid-in capital | 301,842 | 302,994 |
| Accumulated deficit | (58,953) | (40,110) |
| Total stockholders’ equity | 242,902 | 262,897 |
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity | $467,394 | $497,886 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.